HMN 2025: How Transfusing blood from old mice accelerates Alzheimer’s progression in an animal model

Alzheimer’s disease is the most common form of dementia worldwide and continues to be one of the greatest public health challenges. New research, published in the journal Aging, reveals that blood from aged mice can accelerate the progression of the disease, while young blood may have protective effects. The study was led by researchers from Instituto Latinoamericano de Salud Cerebral (BrainLat) at Universidad Adolfo Ibáñez in conjunction with MELISA Institute, the University of Texas Health Science Center at Houston, and Universidad Mayor.

Alzheimer’s is characterized by the abnormal accumulation of beta-amyloid protein (A?) in the brain, forming plaques that disrupt communication between neurons and generate neurodegenerative processes. Although this protein originates in the central nervous system, recent studies have suggested that it may also be present in the blood, opening new possibilities for understanding how the disease progresses.

Study design and methodology explained

To explore this hypothesis, the team used Tg2576 transgenic mice (a model widely used in Alzheimer’s research), which received weekly blood infusions from young and old mice for 30 weeks to assess whether factors present in the blood could modulate amyloid accumulation and the animals’ behavior.

“This collaborative work between various institutions reinforces the importance of understanding how systemic factors condition the brain environment and directly impact mechanisms that promote disease progression. By demonstrating that peripheral signals derived from aged blood can modulate central processes in the pathophysiology of Alzheimer’s, these findings open new opportunities to study therapeutic targets aimed at the blood-brain axis,” explained Dr. Claudia Durán-Aniotz, from the Instituto Latinoamericano de Salud Cerebral (BrainLat) at Universidad Adolfo Ibáñez.

Key findings and proteomic analysis

The team assessed cognitive performance using the Barnes test, the accumulation of amyloid plaques with histological and biochemical techniques, and performed a comprehensive proteomic analysis of the treated brains. This analysis revealed more than 250 differentially expressed proteins, linked to synaptic functions, endocannabinoid signaling, and calcium channels, which could explain the observed changes.

Regarding MELISA Institute’s participation in this research, Mauricio Hernández, a proteomics expert at the research and biotechnology center, commented that “within this study, we conducted a large-scale proteomic analysis that allowed us to generate excellent quality data in this complex matrix like plasma, a technical challenge for any proteomics laboratory. Thanks to our state-of-the-art equipment (timsTOF Pro2), we are proud to have contributed to the production of a robust and high-quality scientific article.”

Implications for future therapies

These results reinforce the idea that circulating factors in the blood can directly influence the progression of neurodegenerative diseases such as Alzheimer’s. Understanding these mechanisms will allow for the identification of new therapeutic targets and preventative strategies. The next step will be to determine exactly what these factors are and whether it is possible to intervene in them in humans.

“It is a pleasure to contribute our proteomic capabilities to support innovative research initiatives like this study, which allow us to advance the knowledge and development of new therapies for neurodegenerative diseases, which are currently a global health problem,” emphasized Dr. Elard Koch, Chairman of MELISA Institute.

Provided by
MELISA Institute

The content is provided for information purposes only.